OR2M4

Across TCGA pan-cancer cohorts, OR2M4 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated OR2M4 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher OR2M4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR2M4 expression acts as an unfavorable survival marker, although some lineages such as SKCM and HNSC show a favorable association.

OV, SCLC, and UCEC are the cancer types where OR2M4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.220	0.541	.032	18	view →
SCLC	DFS	Median	II,III,IV	0.219	0.619	.009	12	view →
UCEC	OS	Median	IV	0.133	0.754	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	12	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	12	view →
SKCM	DFS	Median	II,III,IV	0.600	0.244	.020	7	view →
GBM	OS	Median	All	0.020	0.416	<.001	6	view →
SARC	OS	Median	All	0.174	0.860	<.001	6	view →
HNSC	DFS	Median	III,IV	1.000	0.290	.041	3	view →
LUSC	DFS	Median	III,IV	0.196	0.647	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

OR2M4–OV (DFS)

Open the OV breakdown →